Lavi S, Alemayehu M, Puka K, Wall S, Lavi R. JAMA Cardiol. 2017 Sep 1;2(9):1042-1044.
Dr. Lavi's study was recently covered by Marilynn Larkin of Consultant 360:
Short-term use of ticagrelor is associated with improved microvascular endothelial function but has no effect on arterial stiffness, researchers in Canada say.
Impaired endothelial function is associated with an increased risk of cardiovascular events, whereas use of ticagrelor is associated with reduced risk. To better understand these associations, Dr. Shahar Lavi of Western University in London, Ontario, and colleagues assessed endothelial function and arterial stiffness before and after a dose of a ticagrelor. Assessments were timed to reflect the drug’s peak (two hours after administration) and trough (12 hours after the last dose) concentrations.
Participants had abnormal endothelial function, defined as a reactive hyperemia index (RHI) of less than 2.0, and at least two cardiovascular risk factors: 27% had diabetes, 76% had dyslipidemia, and 64% had hypertension. All but one were taking aspirin; 84% were taking a statin, 76% a beta-blocker, or both.
Source: Larkin, M. (2017, August 4). Ticagrelor tied to acute improvement in endothelial function. HMP Communications LLC: 2017 Aug4. From https://www.consultant360.com/story/ticagrelor-tied-acute-improvement-endothelial-functionRead the full Consultant 360 article here
Read the research letter in JAMA Cardiology